Market revenue in 2022 | USD 50.9 million |
Market revenue in 2030 | USD 82.6 million |
Growth rate | 6.2% (CAGR from 2022 to 2030) |
Largest segment | Viscosupplements |
Fastest growing segment | Synthetic |
Historical data | 2016 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Allografts, Synthetic, Cell-based, Viscosupplements |
Key market players worldwide | Anika Therapeutics Inc, Vericel Corp, Baxter International Inc, Zimmer Biomet Holdings Inc, Stryker Corp, Smith & Nephew PLC, BioTissue, MiMedx Group Inc, Arthrex, AlloSource, VSY Biotechnology, Aptissen |
Key Regions: Brazil , U.S. , UK , Japan , South Africa
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to orthopedic regenerative surgical products market will help companies and investors design strategic landscapes.
Viscosupplements was the largest segment with a revenue share of 41.45% in 2022. Horizon Databook has segmented the Mexico orthopedic regenerative surgical products market based on allografts, synthetic, cell-based, viscosupplements covering the revenue growth of each sub-segment from 2016 to 2030.
Mexico is the second-largest developed economy in Latin America after Brazil. Higher healthcare spending capacity is resulting in greater demand for advanced healthcare services. As a result, adoption of innovative products and minimally invasive surgeries is higher in Mexico.
Increasing demand for products supporting orthopedic surgery is anticipated to propel market growth during the forecast period. In addition, Mexico is a preferred destination for esthetic surgeries due to presence of skilled surgeons and healthcare facilities providing treatment at cheaper costs.
Regulatory product approval process is less stringent since the incorporation of fast-track program in 2010 by COFEPRIS. This program allows the approval of medical devices cleared by the U.S. FDA and Health Canada in 3 to 6 months. However, on the other hand, inadequate reimbursement is one of the major factors hindering growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico orthopedic regenerative surgical products market , including forecasts for subscribers. This country databook contains high-level insights into Mexico orthopedic regenerative surgical products market from 2016 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account